Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design
- PMID: 38484408
- DOI: 10.1016/j.ctrv.2024.102703
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design
Abstract
Choosing the right drug(s) for the right patient via advanced genomic sequencing and multi-omic interrogation is the sine qua non of precision cancer medicine. Traditional cancer clinical trial designs follow well-defined protocols to evaluate the efficacy of new therapies in patient groups, usually identified by their histology/tissue of origin of their malignancy. In contrast, precision medicine seeks to optimize benefit in individual patients, i.e., to define who benefits rather than determine whether the overall group benefits. Since cancer is a disease driven by molecular alterations, innovative trial designs, including biomarker-defined tumor-agnostic basket trials, are driving ground-breaking regulatory approvals and deployment of gene- and immune-targeted drugs. Molecular interrogation further reveals the disruptive reality that advanced cancers are extraordinarily complex and individually distinct. Therefore, optimized treatment often requires drug combinations and N-of-1 customization, addressed by a new generation of N-of-1 trials. Real-world data and structured master registry trials are also providing massive datasets that are further fueling a transformation in oncology. Finally, machine learning is facilitating rapid discovery, and it is plausible that high-throughput computing, in silico modeling, and 3-dimensional printing may be exploitable in the near future to discover and design customized drugs in real time.
Keywords: Biomarkers; Clinical trial design; Master protocol; N-of-1; Precision oncology; Real world data.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Elena Fountzilas has the following financial relationships to disclose: Advisory Role: Amgen. Speaker fees: Pfizer, AstraZeneca, Amgen, GSK. Travel grant: AstraZeneca, Pfizer and Genesis. Stock ownership: Genprex Inc., Deciphera Pharmaceuticals Inc. Dr. Apostolia-Maria Tsimberidou has the following financial relationships to disclose: Clinical Trial Research Funding (Institution): OBI Pharma, Agenus, Parker Institute for Cancer Immunotherapy, Tempus, IMMATICS, Tvardi, Novocure, Tachyon, Orionis; Consulting or Advisory Role: VinceRx, Diaccurate, NEX-I; BrYet, Bioeclipse, Macrogenics, Avstera Therapeutics. Other: Travel: ASCO, Cancer Care Crossroads, Precision Medicine World Conference, GenomeWeb conference. Dr. Henry Hiep Vo reports no relevant conflicts of interest. Dr. Kurzrock has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte,Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance and from the NCI;as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc. and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. RK is funded in part by 5U01CA180888-08 and 5UG1CA233198-05.
Similar articles
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.Cochrane Database Syst Rev. 2025 Mar 24;3(3):CD014872. doi: 10.1002/14651858.CD014872.pub2. Cochrane Database Syst Rev. 2025. PMID: 40122129
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090. Health Technol Assess. 2006. PMID: 16545208
Cited by
-
Novel clinical trial designs emerging from the molecular reclassification of cancer.CA Cancer J Clin. 2025 May-Jun;75(3):243-267. doi: 10.3322/caac.21880. Epub 2025 Jan 22. CA Cancer J Clin. 2025. PMID: 39841128 Free PMC article. Review.
-
Feasibility trial of Darwin OncoTreat and OncoTarget precision medicine testing to improve outcomes for patients with limited metastatic disease that failed first-line systemic therapy.PLoS One. 2025 Jun 11;20(6):e0325769. doi: 10.1371/journal.pone.0325769. eCollection 2025. PLoS One. 2025. PMID: 40498747 Free PMC article.
-
Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology.Pharmaceuticals (Basel). 2025 Jun 18;18(6):915. doi: 10.3390/ph18060915. Pharmaceuticals (Basel). 2025. PMID: 40573308 Free PMC article. Review.
-
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.Med. 2025 Jan 10;6(1):100550. doi: 10.1016/j.medj.2024.11.003. Epub 2024 Dec 16. Med. 2025. PMID: 39689708 Review.
-
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.Oncotarget. 2025 Mar 12;16:140-162. doi: 10.18632/oncotarget.28703. Oncotarget. 2025. PMID: 40073368 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical